Verastem: Novel Drugs Targeting Cancer Stem Cells

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.




January 27, 2016
Verastem to Present at Upcoming Investor Conferences

January 21, 2016
Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016

January 6, 2016
Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer


Cancer Stem Cells

The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.

Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.

Learn More »